Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2010-05-04 Proxy Solicitation & In…
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2010-05-04 English
AMENDMENT NO. 1 TO FORM 10-K
Annual Report FY 2009
2010-04-30 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 22, 2010, by ChromaDex Corporation. It details the entry into a material definitive agreement involving a private placement of common stock and warrants, including terms of the subscription agreement, stockholder approval conditions, board changes contingent on the transaction, and related employment agreements. The content focuses on financing activities, issuance of shares, warrants, and changes in board composition tied to the financing. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The primary subject is the update on capital raising and related corporate governance changes. According to the filing definitions, this fits best under Capital/Financing Update (CAP) because it reports on fundraising and capital structure changes. Although there is mention of board changes, the main focus is the financing transaction, so CAP is more appropriate than MANG. The document is lengthy and detailed, not a brief announcement or certification, so it is not RNS or RPA.
2010-04-26 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'Preliminary Proxy Statement' and references SEC Schedule 14A, which is the standard form for proxy statements filed with the SEC. It includes detailed information about the annual meeting of stockholders, including proposals to be voted on, board of directors nominees, corporate governance, executive compensation, and other matters typically covered in proxy statements. The document also includes a notice of the annual meeting and instructions for voting proxies. The presence of detailed proposals, board nominations, and voting instructions confirms this is a proxy solicitation document. It is not an annual report, earnings release, or other financial report, but rather a solicitation of shareholder votes for the annual meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the full proxy statement, not just an announcement or notice.
2010-04-23 English
AMENDMENT NO.1 TO SCHEDULE 13D
Major Shareholding Notification
2010-04-22 English
A&R EMPLOYMENT AGREEMENTS
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 19, 2010, by ChromaDex Corporation. The key content is the announcement of Amended and Restated Employment Agreements with two executives: Frank L. Jaksch Jr. (CEO and Co-Chairman) and Thomas Varvaro (CFO and director). The document details changes in employment terms, salaries, bonuses, severance, and other compensatory arrangements. The primary focus is on changes in senior management employment agreements, which fits the category of Board/Management Information (MANG). There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a proxy, voting result, or legal proceeding. It is not a report publication announcement or regulatory filing of a different nature. Therefore, the best classification is MANG with high confidence.
2010-04-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.